Prognostic factors and selection for clinical studies of patients with kidney cancer. - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Critical Reviews in Oncology/Hematology Année : 2008

Prognostic factors and selection for clinical studies of patients with kidney cancer.

John S Lam
  • Fonction : Auteur
Tobias Klatte
  • Fonction : Auteur
Hyung L Kim
  • Fonction : Auteur
Alberto Breda
  • Fonction : Auteur
Amnon Zisman
  • Fonction : Auteur
Allan J Pantuck
  • Fonction : Auteur
Robert A Figlin
  • Fonction : Auteur

Résumé

Over the past 2 decades, a greater understanding of the basic biology and genetics of kidney cancer has occurred. Surgical techniques have also evolved, and technological advances have made possible new methods of managing renal tumors. The most extensively used system to provide prognostic information for renal cell carcinoma (RCC) is currently the tumor, nodes, metastasis (TNM) staging system. Emerging data over the last few years has questioned whether further revisions are needed and if improvements can be made with the introduction of new, more accurate and predictive prognostic factors. The recent discovery of molecular tumor biomarkers are expected to revolutionize the staging of RCC and potentially lead to the development of new therapies based on molecular targeting. This review will examine the current staging modalities and prognostic factors associated with RCC as well as the selection of patients most likely to benefit from clinical trials.

Dates et versions

hal-00277599 , version 1 (06-05-2008)

Identifiants

Citer

John S Lam, Tobias Klatte, Hyung L Kim, Jean-Jacques Patard, Alberto Breda, et al.. Prognostic factors and selection for clinical studies of patients with kidney cancer.. Critical Reviews in Oncology/Hematology, 2008, 65 (3), pp.235-62. ⟨10.1016/j.critrevonc.2007.08.003⟩. ⟨hal-00277599⟩
52 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More